Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer - ASCO

open access

 JCO February 4, 2016 

eg.

 In 2015, researchers reported marked gains in overcoming treatment resistance in several difficult-to-treat forms of blood, ovarian, lung, and breast cancers.

 This report features examples of notable research successes achieved thanks to funding from the US National Institutes of Health (NIH), including:

• An early clinical trial that showed that a combination of two novel targeted drugs may slow the growth of a difficult-to-treat form of ovarian cancer.

  The FDA approved two first-in-class therapies, olaparib for the treatment of advanced ovarian cancer and palbociclib for the treatment of advanced breast cancer. Each of these drugs blocks a specific molecule that fuels the growth of that cancer.

  read full text